Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?
March 19, 2024
Register Now!
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
View More
Tislelizumab Approved by FDA For Unresectable or Metastatic Pretreated ESCC
Tislelizumab-jsgr (Tevimbra) has been approved for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) among adult patients who have previously received systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Nivolumab/Chemo Improves Survival in Advanced Gastric/GEJ Cancer
The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Combo Treatment With Brentuximab Vedotin Provides OS Benefit in Previously Treated DLBCL
Treatment for relapsed or refractory diffuse large B-cell lymphoma with brentuximab vedotin, lenalidomide, and rituximab contributed to an improvement in overall survival vs lenalidomide/rituximab/placebo.
Making an Impact on Disparities in Radiotherapy for Breast Cancer
Cancer teams, including oncology nurses, can make conscious choices to potentially alleviate the disparities that persist in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.
Nephroureterectomy, Adjuvant Chemo Extends DFS in Upper Tract Urothelial Cancer
Disease-free survival rates were extended in patients with upper tract urothelial cancer treated with adjuvant chemotherapy after nephroureterectomy compared with those who underwent surveillance.
Cancer Vaccine Plus Nivolumab/Ipilimumab Did Not Improve PFS in Metastatic Melanoma
March 8th 2024Patients with unresectable or metastatic melanoma treated with the universal cancer vaccine UV1 plus nivolumab and ipilimumab did not experience an improvement in progression-free survival vs nivolumab plus ipilimumab alone.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Tracking Symptoms, Physical Activity With Wearable Technology in Oncology Nursing
March 4th 2024Even though wearable technology can track symptoms and physical activity, among other information, in patients with cancer, more research is needed to determine how it all can benefit the management of these patients by oncology nurses.